

## **Product datasheet for TL313583V**

#### OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

### **CYP4B1 Human shRNA Lentiviral Particle (Locus ID 1580)**

#### **Product data:**

**Product Type:** shRNA Lentiviral Particles

Product Name: CYP4B1 Human shRNA Lentiviral Particle (Locus ID 1580)

**Locus ID:** 1580

**Synonyms:** CYPIVB1; P-450HP

**Vector:** pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: CYP4B1 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1

scramble control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM 000779, NM 001099772, NM 001319161, NM 001319162, NM 001319163, NR 135003,

NM 000779.1, NM 000779.2, NM 000779.3, NM 001099772.1, BC017758, BC017758.1,

BM977596, BM982575, NM 001099772.2, NM 000779.4

UniProt ID: P13584

**Summary:** This gene encodes a member of the cytochrome P450 superfamily of enzymes. The

cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes

to the endoplasmic reticulum. In rodents, the homologous protein has been shown to metabolize certain carcinogens; however, the specific function of the human protein has not

been determined. Multiple transcript variants have been found for this gene. [provided by

RefSeq, Jan 2016]

**shRNA Design:** These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact  $\underline{\mathsf{techsupport}} \underline{\mathsf{oorigene.com}}.$ 

If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.







# Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).